Simulations Plus (NASDAQ:SLP – Get Free Report) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 1.070-1.200 for the period. The company issued revenue guidance of $90.0 million-$93.0 million, compared to the consensus revenue estimate of $91.8 million. Simulations Plus also updated its FY25 guidance to $1.07 to $1.20 EPS.
Simulations Plus Price Performance
Shares of NASDAQ:SLP traded down $0.89 during midday trading on Friday, hitting $30.07. 182,114 shares of the company’s stock were exchanged, compared to its average volume of 129,619. The stock has a 50 day moving average price of $33.20 and a 200-day moving average price of $40.76. The company has a market cap of $601.70 million, a PE ratio of 64.50 and a beta of 0.69. Simulations Plus has a 12 month low of $29.37 and a 12 month high of $51.22.
Simulations Plus (NASDAQ:SLP – Get Free Report) last posted its earnings results on Wednesday, October 23rd. The technology company reported $0.06 EPS for the quarter, topping the consensus estimate of $0.04 by $0.02. The company had revenue of $18.70 million during the quarter, compared to the consensus estimate of $19.73 million. Simulations Plus had a net margin of 14.36% and a return on equity of 7.80%. The firm’s revenue for the quarter was up 19.9% on a year-over-year basis. During the same period in the previous year, the firm posted $0.18 earnings per share. On average, analysts anticipate that Simulations Plus will post 0.54 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Check Out Our Latest Stock Report on SLP
Insider Transactions at Simulations Plus
In other news, Director Walter S. Woltosz sold 20,000 shares of the stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $39.63, for a total value of $792,600.00. Following the transaction, the director now owns 3,521,592 shares of the company’s stock, valued at $139,560,690.96. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders have sold 60,750 shares of company stock valued at $2,145,055 in the last quarter. Insiders own 20.90% of the company’s stock.
Simulations Plus Company Profile
Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.
Featured Articles
- Five stocks we like better than Simulations Plus
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Texas Roadhouse Stock Steering for New Highs This Year
- What is Put Option Volume?
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.